Suhail Ayesh

Corporate Officer/Principal presso The Hebrew University of Jerusalem

Health Technology

Consumer Services

Profilo

Suhail Ayesh is Senior Researcher of BioCancell Therapeutics, Inc. He is Professor of Molecular Biochemistry and Gene Therapy at the Hebrew University of Jerusalem.
Mr. Ayesh is a Director of the Molecular Genetics Laboratory for Makassed Hospital.

Posizioni attive di Suhail Ayesh

Società	Posizione	Inizio
The Hebrew University of Jerusalem	Corporate Officer/Principal	-
Al-Makassed Hospital	Corporate Officer/Principal	-

Tutte le posizioni attive di Suhail Ayesh

Precedenti posizioni note di Suhail Ayesh

Società	Posizione	Fine
BioCancell Therapeutics, Inc. BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.	Direttore Tecnico/Scientifico/R&S	-

Vedi nel dettaglio l'esperienza di Suhail Ayesh

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Suhail Ayesh

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
BioCancell Therapeutics, Inc. BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.	Health Technology
Al-Makassed Hospital